Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic. - Wikidata - wikimedia - TriplyDB

Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic.

Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic.

http://www.wikidata.org/entity/Q34345195

about

Oligodendrogenesis in the normal and pathological central nervous system How to make an oligodendrocyte Biomaterial Approaches to Enhancing Neurorestoration after Spinal Cord Injury: Strategies for Overcoming Inherent Biological Obstacles Blocking LINGO-1 in vivo reduces degeneration and enhances regeneration of the optic nerve.Remyelination therapy goes to trial for multiple sclerosis Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033 The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis.The potential of LINGO-1 as a therapeutic target for essential tremor.A new in vitro mouse oligodendrocyte precursor cell migration assay reveals a role for integrin-linked kinase in cell motility Demyelination as a rational therapeutic target for ischemic or traumatic brain injury.Nogo-A and its functions beyond axonal inhibition: the controversial role of Nogo-A in Parkinson's disease Neural Stem Cells Engineered to Express Three Therapeutic Factors Mediate Recovery from Chronic Stage CNS Autoimmunity Nogo receptor blockade overcomes remyelination failure after white matter stroke and stimulates functional recovery in aged mice Disease-modifying treatments for progressive multiple sclerosis.Novel therapeutic options for multiple sclerosis.Established and novel disease-modifying treatments in multiple sclerosis.Remyelination and multiple sclerosis: therapeutic approaches and challenges.Strategies for myelin regeneration: lessons learned from development.Remyelination in multiple sclerosis: cellular mechanisms and novel therapeutic approaches.From demyelination to remyelination: the road toward therapies for spinal cord injury.Progressive MS: from pathophysiology to drug discovery.Extracellular cues influencing oligodendrocyte differentiation and (re)myelination Further understanding of the immunopathology of multiple sclerosis: impact on future treatments.Mechanisms of Axonal Damage and Repair after Central Nervous System Injury.Nogo-A Antibodies for Progressive Multiple Sclerosis.Restoration of Visual Function by Enhancing Conduction in Regenerated Axons LINGO-1 and AMIGO3, potential therapeutic targets for neurological and dysmyelinating disorders?Biallelic variants in LINGO1 are associated with autosomal recessive intellectual disability, microcephaly, speech and motor delay.Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis.HTLV-1-associated myelopathy/tropical spastic paraparesis.LINGO-1-Fc-Transduced Neural Stem Cells Are Effective Therapy for Chronic Stage Experimental Autoimmune Encephalomyelitis.Effect of glial cells on remyelination after spinal cord injury.Anti-LINGO-1 has no detectable immunomodulatory effects in preclinical and phase 1 studies.Clinical implications of myelin regeneration in the central nervous system.Multiple Sclerosis: Basic and Clinical.Cell-based therapeutic strategies for multiple sclerosis.Anti lingo 1 (opicinumab) a new monoclonal antibody tested in relapsing remitting multiple sclerosis.p75NTR and TROY: Uncharted Roles of Nogo Receptor Complex in Experimental Autoimmune Encephalomyelitis."A new imaging modality to non-invasively assess multiple sclerosis pathology".Matrine Treatment Blocks NogoA-Induced Neural Inhibitory Signaling Pathway in Ongoing Experimental Autoimmune Encephalomyelitis.

P2860

Q21129352-978989D0-0F1B-465B-8AFD-0699D5DE0FDB Q26775534-985CFA49-D43C-4EAE-A78C-29DD7580D5FE Q26780494-621C6CA5-D953-4CB8-8973-8DA5649B5D80 Q33692583-CF89584B-64B4-4FA7-8551-27039E3E6FE5 Q34368564-16C83F5E-6B07-4DA1-8AF1-3A2A7662F6EB Q34368617-6227721D-3E7C-4F75-AFE7-77EF48B7C726 Q34468304-93276C42-F97E-4BB4-80AC-3403E859C98F Q34471202-EEC24747-BE1A-4345-85F7-C8032BC53E11 Q35910607-0C6EA02B-4BAA-4DA5-9BC2-D984BF5FA9CD Q36090107-D30E8AA9-3D33-4BF3-88B9-26ED2BF10F90 Q36110712-B4BD7CC1-3941-49D3-BD5E-385213D5C5D5 Q37256159-495E9D55-F2F9-40E0-9DC8-07F3F9652C03 Q37549901-14B93DD8-4483-44D2-8120-55242D037043 Q38142030-9098F991-FCAF-4435-BFBF-66FDDBD7E118 Q38170129-028C15A5-949F-4BD0-ABC4-949A8FAD2AA2 Q38180157-5D804572-89EA-4606-9694-0A22288704A7 Q38238466-90BD33F1-6B7C-4781-9997-89F0F036B8BC Q38249189-FEB31391-F166-4354-B780-026CF5B70F50 Q38257152-1C824C8A-9078-47DF-9381-B2259A2CAE9A Q38366783-176E1FB8-AD12-4D49-899A-6DF183B2A26B Q38585418-C321C0F9-C31D-4981-897B-D0B70F251ED8 Q38789322-037EE5C1-B18B-4616-A284-2868128A7C15 Q38837294-9689C469-3005-43E7-A186-96554ACF6263 Q38938539-14B5D474-0866-4039-B96F-B5C9767B83F5 Q39010894-9F4C8629-D8CF-427E-8CAE-8EDD3ECB4C20 Q41405823-C3F66CF8-29EF-48E0-9E52-2C3DFA5C9600 Q41855417-BC0C93D1-640F-4F9A-A5E8-CA3468B4A80F Q41918634-85342172-F8AC-461F-9461-B782E6009A4C Q41975587-A81D0A17-B8C4-48A0-9C2A-963D81397A1C Q45096240-F1E3D1A8-240A-4B99-A081-7758A1C3D29F Q45855575-9F5B1EA1-77CB-4251-9FF8-173D9DCBB98F Q47094040-70EFA271-84E6-4F20-83A3-10AC09F02992 Q47094091-5E4D18CE-4631-48AA-8E35-D0E9BD237EED Q47276728-CED946FC-27C7-4C26-995D-ACFDB22711A4 Q47677846-12C3430C-13D3-42DE-916D-A6B0AC738547 Q47885870-B653745E-66C6-4144-ABF0-8C3027653413 Q47958350-245DD827-5901-43D1-9DEA-324348C9F5C9 Q48320605-3CC59F32-32B3-40AC-B599-17150C645E63 Q48463290-66AD2329-20D2-4756-A1A9-70D8AAED41D4 Q51277664-E698101A-51C6-4FFB-A7EF-139D2AF1C335

P2860

Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic.

http://www.wikidata.org/entity/Q34345195

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic.

@ast

Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic.

@en

Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic.

@nl

type

label

Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic.

@ast

Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic.

@en

Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic.

@nl

prefLabel

Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic.

@ast

Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic.

@en

Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic.

@nl

P1433

Q34345195-59A5B308-1EC0-4232-B85A-B2841AA71798

P1476

Q34345195-16BCE52D-F99A-4175-A9E6-E22E3BA35287

P2093

Q34345195-21DD7013-8294-43C9-B550-FD2DA984BC1F

Q34345195-5A667254-E7FF-4ACE-A27C-1BCE7AEEBAB6

Q34345195-6AEBB84B-A404-4329-8908-730919CD0A5E

P2860

Q34345195-047A26CA-B0BD-4294-8E12-E7D28DABFF01

Q34345195-0A095B57-1B1B-4818-8194-AFCD64C19BF6

Q34345195-0B89B590-2827-4D7F-8F89-A12D407F4A2F

Q34345195-0DAF86E0-9B13-4359-9640-0AFF521EB1B9

Q34345195-0DED0A74-4763-4795-9E8A-91A908E1287F

Q34345195-159180F3-BE5A-49BA-AEE7-5694F94B18A6

Q34345195-226C7254-21F3-4D6C-B44A-5A6E10B41ECF

Q34345195-236C99FA-0BC4-4C99-A827-F4C51C314A29

Q34345195-258F21AE-7246-4C10-9B75-F414898C4F43

Q34345195-2B9658FF-DC8D-4139-90C6-46522C110074

P2888

Q34345195-F69E17DA-02E9-4F24-911A-2F3D661BE9EF

P304

Q34345195-87B0D4D7-65EE-4A97-ACDC-0D12A7574C51

P31

Q34345195-DED06238-55BD-48A4-B799-DD7C5D48D370

P356

Q34345195-C88FA2BA-57AD-46F3-8E0B-C8D27521175C

P433

Q34345195-B545067F-231F-4AE0-96D6-6EC42378B457

P478

Q34345195-A5E8C492-08C8-4B5D-AC22-A1AFE36CCA53

P577

Q34345195-466C7E90-43F3-446F-806F-E50CB148684A

P698

Q34345195-CA2329B5-BFC4-4B29-B872-CE827FA423C2

P356

S40263-013-0068-8

P1433

P1476

Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic.

@en

P2093

Diego Cadavid

http://www.w3.org/2001/XMLSchema#string

R Blake Pepinsky

http://www.w3.org/2001/XMLSchema#string

Sha Mi

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration

AMIGO, a transmembrane protein implicated in axon tract development, defines a novel protein family with leucine-rich repeats

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models

LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex.

Multiple sclerosis

Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation

Crossroads in GDNF therapy for Parkinson's disease

A TNF receptor family member, TROY, is a coreceptor with Nogo receptor in mediating the inhibitory activity of myelin inhibitors

LINGO-1 negatively regulates myelination by oligodendrocytes

P2888

s40263-013-0068-8

P304

493-503

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40263-013-0068-8

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23681979

http://www.w3.org/2001/XMLSchema#string